Clinuvel’s US Filing For EPP Drug Scenesse Includes Real World Evidence From Europe

 
• By Ian Schofield

Clinuvel says real world evidence from the experience of European patients is a key part of the submission it has just made to the US FDA for its ground-breaking phototoxicity therapy, Scenesse (afamelanotide). The company also plans to apply its one-price policy for the product in the US.

Sumbit
Scenesse has submitted its phototoxicity drug Scenesse for US approval

More from United States

More from North America